Chemogenomic Analysis of Safety Profiling Data

Methods in Molecular Biology

Volumn 575, Issue , 2009, Pages 207-223

  Scheiber, Josef ^a   Jenkins, Jeremy L ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Chemogenomics; Data Mining; Drug Safety; Safety profiling

Indexed keywords

ARTICLE; BAYES THEOREM; DRUG DEVELOPMENT; DRUG SCREENING; DRUG TOXICITY; GENOMICS; MOLECULAR BIOLOGY; PRINCIPAL COMPONENT ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICS;

BAYES THEOREM; DATA INTERPRETATION, STATISTICAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; GENOMICS; MODELS, STATISTICAL; MOLECULAR BIOLOGY; PRINCIPAL COMPONENT ANALYSIS;

MLCS; MLOWN;

EID: 75549084459     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-60761-274-2_9     Document Type: Chapter

References (11)

1. Whitebread, S., Hamon, J., Bojanic, D., and Urban, L. (2005) Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov. Today 10, 1421–1433.
2. Morgan, H. L. (1965) Generation of a unique machine description for chemical structures–a technique developed at Chemical Abstracts Service. J. Chem. Doc. 5, 107.
3. Nidhi, Glick, M., Davies, J.W., and Jenkins, J.L. (2006) Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases. J. Chem. Inf. Model. 46, 1124– 1133.
4. Xia, X., Maliski, E. G., Gallant, P., and Rog-ers, D. (2004) Classification of kinase inhib-itors using a Bayesian model. J. Med. Chem. 47, 4463–4470.
5. Klon, A. E., Glick, M., and Davies, J.W. (2004) Application of machine learning to improve the results of high-throughput docking against the HIV-1 protease. J. Chem. Inf. Comput. Sci. 44, 2216–2224.
6. Hert, J., Willett, P., Wilton, D. J., Acklin, P., Azzaoui, K., Jacoby, E., and Schuffenhauer, A. (2006)Newmethods for ligand-based virtual screening: use of data fusion and machine learning to enhance the effectiveness of similarity searching. J. Chem. Inf. Model. 46, 462–470.
7. Whitebread, S., Hamon, J., Bojanic, D., and Urban, L. (2005) Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov. Today 10, 1421–1433.
8. Hopkins, A. L., Mason, J. S., and Overing-ton, J. P. (2006) Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 16, 127–136.
9. Azzaoui, K., Hamon, J., Faller, B., White-bread, S., Jacoby, E., Bender, A., Jenkins, J. L., and Urban, L. (2007) Modeling promiscuity based on in vitro safety pharmacology profiling data. ChemMedChem 2, 874–880.
10. Yildirim, M. A., Goh, K. I., Cusick, M. E., Barabasi, A. L., and Vidal, M. (2007) Drug-target network. Nat. Biotech. 25, 1119– 1126.
11. Bender, A., Scheiber, J., Glick, M., Davies, J. W., Azzaoui, K., Hamon, J., Urban, L., Whitebread, S., and Jenkins, J. L. (2007) Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMed-Chem 2, 861–873.